GERON JPM-2025-Corporate-Slides_final-2.pdf

《GERON JPM-2025-Corporate-Slides_final-2.pdf》由会员分享，可在线阅读，更多相关《GERON JPM-2025-Corporate-Slides_final-2.pdf（35页珍藏版）》请在三个皮匠报告上搜索。

1、Corporate PresentationOur mission is to change lives by changing the course of blood cancerJanuary 2025Our mission is to change lives by changing the course of blood cancer2Forward-Looking StatementsExcept for the historical information contained herein,this presentation contains forward-looking sta

2、tements made pursuant to the“safe harbor”provisions of the Private Securities Litigation Reform Act of 1995.Investors are cautioned that such statements,include,without limitation,those regarding:(i)the Companys belief that RYTELO is a highly differentiated treatment with blockbuster potential for e

3、ligible LR-MDS patients,including the potential to achieve$1B+in net revenue;(ii)the Companys estimate of net revenues for the fourth quarter of 2024;(iii)the Companys views,estimates and expectations concerning the commercial launch of RYTELO,including the size of market opportunity and ability to

4、compete for market share;(iv)the Companys assumptions and expectations regarding the expected commercial opportunity for RYTELO in R/R MF;(v)the Companys projections of its ability to reach profitability without the need for additional financing if internal revenue and operating expense expectations

5、 are met;(vi)the potential for differentiated benefits associated with RYTELOs mechanism of action;(vii)the Companys views,estimates and expectations concerning the commercial launch of RYTELO,including size of market opportunity and ability to compete for market share;(viii)the potential impact on

6、clinical decision-making,prescriber behavior,and reimbursement decisions of the inclusion of RYTELO in the NCCN Guidelines as a Category 1 and 2A treatment of symptomatic anemia in patients with lower-risk MDS and the favorability of RYTELOs U.S.labeling;(ix)the market opportunity for RYTELO and the